Johns Hopkins University
3400 North Charles Street
Baltimore
Maryland
21218
United States
Tel: 410-516-8000
Website: http://www.jhu.edu/
689 articles about Johns Hopkins University
-
LifeSprout Enters into Licensing Agreement with Boyang Trading to Develop and Commercialize Next-Generation Lumina™ Dermal Filler in Greater China
1/31/2024
LifeSprout announced it has entered into a definitive agreement with Boyang Trading Co., Ltd. to exclusively develop and commercialize the Lumina™ dermal filler in mainland China, Hong Kong, Macau, and Taiwan.
-
Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work
1/17/2024
Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.
-
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
12/13/2023
Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 "New Angiogenesis Inhibitors".
-
AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.
-
The FDA plans to review changes to Novavax’s manufacturing process before it authorizes its vaccine.
-
BioSpace looks at the challenges faced by the Latinx community in the life sciences, from the origins of the challenges, to educational gain and the importance of mentorship.
-
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
-
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here's a look at that story and more COVID-19 news.
-
As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.
-
Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University
3/31/2022
Tevard Biosciences today announced an agreement to exclusively license "mRNA Amplifier" technology will help form the basis of Tevard's third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.
-
Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research
3/3/2022
LOVE Pharma Co. is pleased to announce updated details on the proposed Microdoz Therapy acquisition whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University to conduct a landmark study into the potential of psilocybin assisted treatment of cannabis use disorder.
-
There's always more to learn about Parkinson's, and researchers discovered a specialized group of neurons associated with the disease.
-
95% of those surveyed agreed that the pandemic showed the vulnerabilities of the medicine supply chain.
-
New Study Validates Novel Markers for Detecting Microsatellite Instability in Multiple Cancers
2/3/2022
Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors.
-
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
-
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
-
A team of researchers has developed an mRNA-based Lyme vaccine that aims to prevent Lyme disease by deterring the tick itself. And here's how effective it is.
-
Precision Molecular Inc. Executes License for Exclusive Rights to an Astatine-211-Labeled Radiopharmaceutical Inhibitor of Prostate-Specific Membrane Antigen for Prostate Cancer Therapeutics
12/21/2021
Precision Molecular, Inc. today announced it has executed a licensing agreement with Johns Hopkins University for exclusive rights to an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA) which is typically elevated in prostate cancer cells.
-
Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care
12/9/2021
Proximie has teamed up with Jhpiego, a Johns Hopkins University affiliate, on a safe surgery project in Kenya to layer in their unique software that allows physicians anywhere in the world to virtually "scrub-in" and mentor colleagues in real time.
-
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
10/5/2021
Mydecine Innovations Group announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University, New York University and the University of Alabama Birmingham by leading drug and substance use researcher, Dr. Matthew Johnson.